Clinical Trial Update: Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating fludarabine in combination with alemtuzumab or rituximab in patients with refractory or relapsed B-cell chronic lymphocytic le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Fludarabine (Fludarabine)
• Rituximab (rituximab)

Snippet

Sponsor: Bayer | Conditions: Leukemia | Phase 2 | Status: COMPLETED